| Today's Big NewsNov 9, 2022 |
|
Talent matters more than ever. And Greater Philadelphia’s growth and development of this critical asset is one reason JLL ranked the region as its No. 5 Life Sciences cluster in the U.S. Learn how the region can fuel your company’s growth. Learn more.
|
|
| By Angus Liu After weeks of an inspection-related delay, Regeneron has finally won a much-anticipated FDA approval for Libtayo in newly diagnosed non-small cell lung cancer, opening another front to challenge Merck & Co.’s formidable Keytruda. |
|
|
|
By Nick Paul Taylor Biotech earnings season has delivered a deck of dead and deprioritized assets, with Xilio Therapeutics, Protagonist Therapeutics, Arbutus Biopharma and Aptinyx all deciding they have better uses for their cash. |
By Dave Muoio Mass General Brigham said its new "Patient Code of Conduct" was developed over the course of the year as a direct response to a "national rise in violence and hostile behavior at healthcare facilities." |
By Andrea Park With Peter Shen, Ph.D., set to retire at the end of this year, the company found a new global head of medtech innovation and R&D in Ahmet Tezel, Ph.D. |
|
Wednesday, November 16, 2022 | 11am ET / 8am PT Process characterization is an important step in the product development journey. Join this webinar where experts share case studies in developing a stepwise approach for process validation. Register now.
|
|
By Kevin Dunleavy With uptake slow in the United States for its long-awaited COVID-19 vaccine, Novavax has adjusted its revenue projection for 2022. Instead of guiding to a range of $2 to $2.3 billion, the company has dropped the upper end, estimating revenue will come in at $2 billon. Six months ago, the company was guiding to a 2022 revenue figure between $4 and $5 billion. |
By Annalee Armstrong A new, slimmed-down Biohaven issued its debut earnings release post-Pfizer split, touting a $301.9 million fundraising, new executive staffers and pipeline stocked with therapies to test in epilepsy and neuropsychiatric conditions. |
By Anastassia Gliadkovskaya Reducing waste in the system has become a key priority for many healthcare organizations. Working with vendors, health systems and payers are leveraging artificial intelligence, machine learning, data analytics and other technologies to improve billing and payment processes. |
By Conor Hale “In diagnostics, we have come to the conclusion that the dramatically changed macroeconomic environment demands immediate and comprehensive measures,” CEO Bernd Montag said during the company’s earnings call. |
By Fraiser Kansteiner After making its debut in Denmark, Novo Nordisk's pre-filled pen recycling pilot has expanded to Brazil and recently also launched in the U.K., Katrine DiBona, the company's corporate vice president of global public affairs and sustainability, said in an interview. |
By Heather Landi Hims & Hers shares rose 25% Tuesday as investors were buoyed by the direct-to-consumer health and wellness brand's sunny outlook for the remainder of the year. |
By Andrea Park Outset's ongoing recovery from a shipping hold on its portable dialysis machines over the summer has outpaced the company's own revenue expectations, CEO Leslie Trigg said during a third-quarter earnings call Tuesday. |
By Max Bayer Some 48 hours after Amgen touted updated phase 2 data for its Arrowhead Pharmaceuticals-partnered heart drug, Royalty Pharma is swooping in to pick up royalty rights from the small biopharma to the tune of $250 million in upfront cash. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| WhitepaperClarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| WhitepaperLearn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
